COPD and Asthma Devices Market by Inhalers Type (Drug powder, Metered Dose, Soft Mist), Nebulizers (Compressor, Ultrasonic, Mesh) - Global Opportunity Analysis and Industry Forecasts, 2015 - 2022

Description:
Asthma is a chronic respiratory disease blocking the airways of the lungs because of the inflammation, mucus production, tighten of muscles. The general symptoms are coughing, wheezing, shortness of breath and/or chest tightness and majorly these symptoms are closely related to the physical activity. There are different types of asthma, exercise-induced bronchoconstriction(EIB), allergic asthma, occupational asthma, childhood asthma. Chronic Obstructive Pulmonary Disease (COPD) is also respiratory disease which causes obstructions and difficulty in breathing, the primary cause of COPD is tobacco smoking and chemical flumes, dust, air pollution are minor causes of the disease. Major symptoms are long lasting cough, mucus that comes out along with cough, shortness of breath.

The world COPD and asthma drugs market is expected to reach $50,359 million by 2022, growing at a CAGR of 3.7% from 2016 to 2022. Increase in prevalence of asthma and COPD, increase in world ageing population, technological advancement in the treatment of asthma and COPD, growth in initiatives implemented by the government and non-government associations for rise in health awareness play a pivotal role in the growth of the global COPD and asthma drug market. Stringent government regulatory requirement for the approval of COPD and asthma drug, patent expiry of branded hamper the market growth.

The world asthma and COPD drugs market is segmented based on disease and medication class and geography. On the basis of disease, the market is segmented into COPD and asthma. Based on medication class, the world asthma and COPD drug market is segmented into combination products, short acting beta agonists (SABA), long acting beta agonists (LABA), inhaled corticosteroids (ICS), leukotriene antagonists (LTA), anticholinergics and others. And geographically, the market is segmented into North America, Europe, Asia-Pacific, and LAMEA.

Key Benefits:
The study provides an in-depth analysis of the asthma and COPD drug market with current trends and future estimations to elucidate the imminent investment pockets in the market.
The report provides a quantitative analysis from 2014 to 2022 to enable the stakeholders to capitalize on prevailing market opportunities.
Extensive analysis of the asthma and COPD drug market, by medication class, helps in the treatment of asthma and COPD diseases.
Competitive intelligence highlights the business practices followed by leading market players across various geographic regions.
Key market players within the asthma and COPD drug market are profiled in this report and their strategies are analyzed thoroughly, which predicts the competitive outlook of global asthma and COPD drug market.
Key market segments
The world COPD and asthma drug market is segmented by medication class, disease and geography.

MARKET BY DISEASES
COPD
Asthma

MARKET BY MEDICATION CLASS
Combination Products
Seretide/Advair
Symbicort
Relvar/Breo Ellipta
Flutiform
Dulera
Others
Leukotriene Antagonists (LTA)
Singulair
Others
Inhaled Corticosteroids (ICS)
Qvar
Pulmicort
Aerospan
Flovent
Others
Anticholinergics
Spiriva
Others
Short Acting Beta Agonists (SABA)
ProAir
Ventolin
Others
Long Acting Beta Agonists (LABA)
Others

MARKET BY GEOGRAPHY

North America
U.S.
Canada
Mexico
Europe
U.K.
France
Germany
Italy
Rest of Europe
Asia-Pacific
Japan
China
India
Rest of Asia-Pacific
LAMEA
Latin America
Middle East
Africa

Contents:

CHAPTER 1 INTRODUCTION
1.1 Report description
1.2 Key benefits
1.3 Key market segments
1.4 Research methodology
1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY
2.1 CXO perspective

CHAPTER 3 MARKET OVERVIEW
3.1 Market definition and scope
3.2 Key findings
3.2.1 Top investment pockets
3.2.2 Top winning strategies

3.3 Porters five forces analysis
3.3.1 Bargaining power of buyers (High)
3.3.2 Bargaining power of suppliers (Low to Moderate)
3.3.3 Threat of new entrants (Low)
3.3.4 Threat of substitutes (High)
3.3.5 Intense competitive rivalry

3.4 Market dynamics

3.4.1 Drivers
3.4.1.1 Increase in number of asthmatic and COPD patients worldwide
3.4.1.2 Increase in world ageing population
3.4.1.3 Technological advancement in the treatment of asthma and COPD drugs
3.4.1.4 Initiatives taken by various government associations to raise awareness about diagnosis and management of asthma and COPD
3.4.1.5 Increasing number of products in the pipeline

3.4.2 Restraints
3.4.2.1 Stringent regulatory requirements for the approval and commercialization of asthma and COPD drugs
3.4.2.2 Asthma and COPD drugs show side effects
3.4.2.3 Asthma and COPD drug approval process is expensive and time-consuming
3.4.2.4 Patent expiry of asthma and COPD drugs

3.4.3 Opportunities
3.4.3.1 Introduction of generic drugs of asthma and COPD drugs

3.5 Market share analysis, 2015

CHAPTER 4 GLOBAL ASTHMA AND COPD DRUGS MARKET, BY DISEASE
4.1 Overview
4.2 Asthma
4.2.1 Global prevalence
4.2.2 Key growth factors and opportunities
4.2.3 Market size and forecast

4.3 COPD
4.3.1 Global prevalence
4.3.2 Key growth factors and opportunities
4.3.3 Market size and forecast

CHAPTER 5 GLOBAL ASTHMA AND COPD DRUGS MARKET, BY MEDICATION CLASS
5.1 Overview
5.2 Combination Drugs
5.2.1 Market size and forecast
5.2.2 Seretide/Advair
5.2.3 Symbicort
5.2.4 Relvar/Breo Ellipta
5.2.5 Flutiform
5.2.6 Dulera
5.3 Leukotriene antagonists (LTA)
  5.3.1 Market size and forecast
  5.3.2 Singulair

5.4 Inhaled corticosteroids (ICS)
  5.4.1 Market size and forecast
  5.4.2 Qvar
  5.4.3 Pulmicort
  5.4.4 Aerospan
  5.4.5 Flovent

5.5 Anticholinergics
  5.5.1 Market size and forecast
  5.5.2 Spiriva

5.6 Short acting beta agonists (SABA)
  5.6.1 Market size and forecast
  5.6.2 ProAir
  5.6.3 Ventolin

5.7 Long acting beta agonists (LABA)
  5.7.1 Market size and forecast

5.8 Others
  5.8.1 Market size and forecast

CHAPTER 6 GLOBAL ASTHMA AND COPD DRUGS MARKET, BY GEOGRAPHY, 2015-2022

6.1 Overview
  6.1.1 Market size and forecast

6.2 North America
  6.2.1 Key market trends
  6.2.2 Key growth factors and opportunities
  6.2.3 Market size and forecast
  6.2.4 U.S.: market size and forecast
  6.2.5 Canada market size and forecast
  6.2.6 Mexico: market size and forecast

6.3 Europe
  6.3.1 Key market trends
  6.3.2 Key growth factors and opportunities
  6.3.3 Germany: market size and forecast
  6.3.4 France market size and forecast
  6.3.5 UK: market size and forecast
  6.3.6 Italy market size and forecast
  6.3.7 Rest of Europe: market size and forecast

6.4 Asia-Pacific
  6.4.1 Key market trends
  6.4.2 Key growth factors and opportunities
  6.4.3 Market size and forecast
  6.4.4 Japan: market size and forecast
6.4.5 China market size and forecast
6.4.6 India: market size and forecast
6.4.7 Rest of Asia-Pacific market size and forecast

6.5 LAMEA

6.5.1 Key market trends
6.5.2 Key growth factors and opportunities
6.5.3 Market size and forecast
6.5.4 Latin America: market size and forecast
6.5.5 Middle East market size and forecast
6.5.6 Africa: market size and forecast

CHAPTER 7 GLOBAL ASTHMA AND COPD DRUGS PIPELINE -2015

CHAPTER 8 COMPANY PROFILES

8.1 Boehringer Ingelheim International GmbH

8.1.1 Company overview
8.1.2 Operating business segments
8.1.3 Business performance
8.1.4 Key strategic moves & developments

8.2 Merck & Co., Inc.

8.2.1 Company overview
8.2.2 Operating business segments
8.2.3 Business performance
8.2.4 Key strategic moves & developments

8.3 GlaxoSmithKline PLC.

8.3.1 Company overview
8.3.2 Operating business segments
8.3.3 Business performance
8.3.4 Key strategic moves & developments

8.4 Novartis AG

8.4.1 Company overview
8.4.2 Operating business segments
8.4.3 Business performance
8.4.4 Key strategic moves & developments

8.5 AstraZeneca

8.5.1 Company overview
8.5.2 Operating business segments
8.5.3 Business performance
8.5.4 Key strategic moves & developments

8.6 F. Hoffmann-La Roche Ltd

8.6.1 Company overview
8.6.2 Operating business segments
8.6.3 Business performance
8.6.4 Key strategic moves & developments

8.7 Teva Pharmaceutical Industries Ltd.

8.7.1 Company overview
8.7.2 Operating business segments
8.7.3 Business performance
8.7.4 Key strategic moves & developments

8.8 Vectura Group plc.
8.8.1 Company overview
8.8.2 Operating business segments
8.8.3 Business performance
8.8.4 Key strategic moves & developments

8.9 Pfizer, Inc.
8.9.1 Company overview
8.9.2 Operating business segments
8.9.3 Business performance
8.9.4 Key strategic moves & developments

8.10 Abbott Laboratories
8.10.1 Company overview
8.10.2 Operating business segments
8.10.3 Business performance
8.10.4 Key strategic moves & developments

Order by Fax - using the form below
Order by Post - print the order form below and send to

    Research and Markets,
    Guinness Centre,
    Taylors Lane,
    Dublin 8,
    Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: COPD and Asthma Devices Market by Inhalers Type (Drug powder, Metered Dose, Soft Mist), Nebulizers (Compressor, Ultrasonic, Mesh) - Global Opportunity Analysis and Industry Forecasts, 2015 - 2022
Web Address: http://www.researchandmarkets.com/reports/3046126/
Office Code: SC

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 5370</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 5 Users:</td>
<td>USD 5910</td>
</tr>
<tr>
<td>Enterprisewide:</td>
<td>USD 7800</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title:  
Mr ☐  Mrs ☐  Dr ☐  Miss ☐  Ms ☐  Prof ☐

First Name:  
Last Name:  

Email Address: *  

Job Title:  
Organisation:  
Address:  
City:  
Postal / Zip Code:  
Country:  
Phone Number:  
Fax Number:  

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by Wire Transfer: Bank details will be provided on the invoice which you will receive after you place your order with us.

If you have a Marketing Code please enter it below:

Marketing Code: __________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World